Warning: The NCBI web site requires JavaScript to function. more...
Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
Yuan ZG, Dun XY, Li YH, Hou J.
J Hematol Oncol. 2009 Apr 28;2:19.
Related citations
Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant).
Sobas MA, Alonso Vence N, Diaz Arias J, Bendaña Lopez A, Fraga Rodriguez M, Bello Lopez JL.
Ann Hematol. 2010 Feb;89(2):217-9. Epub 2009 Jul 28. No abstract available.
Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A.
AIDS Rev. 2008 Jan-Mar;10(1):25-35. Review.
Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease.
Wang X, Ye S, Xiong C, Gao J, Xiao C, Xing X.
Jpn J Clin Oncol. 2011 Oct;41(10):1221-4. Epub 2011 Sep 2.
POEMS syndrome, osteosclerotic myeloma and Castleman's disease: a case report.
Bosco J, Pathmanathan R.
Aust N Z J Med. 1991 Aug;21(4):454-6.
[Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
Huang WR, Li R, Jing Y, Zhang YZ, Wu XX, Gao CJ, Bo J, Yu L, Wang QS, Da WM.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Dec;14(6):1146-50. Chinese.
HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
Nicoli P, Familiari U, Bosa M, Allice T, Mete F, Morotti A, Cilloni D, Saglio G, Guerrasio A.
Int J Hematol. 2009 Oct;90(3):392-6. Epub 2009 Sep 12.
Splenectomy induced complete remission in a patient with multicentric Castleman's disease and autoimmune hemolytic anemia.
Lerza R, Castello G, Truini M, Ballarino P, Tredici S, Cavallini D, Pannacciulli I.
Ann Hematol. 1999 Apr;78(4):193-6.
[Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP].
Pastor MA, Vasco B, Mosquera JM, Debén G, Bautista P, Requena L.
Actas Dermosifiliogr. 2006 Jul-Aug;97(6):385-90. Review. Spanish.
Hematology: first-line bortezomib benefits patients with multiple myeloma.
Dimopoulos MA, Terpos E.
Nat Rev Clin Oncol. 2009 Dec;6(12):683-5.
Multicentric Castleman's disease in association with Kaposi's sarcoma.
De Rosa G, Barra E, Guarino M, Gentile R.
Appl Pathol. 1989;7(2):105-10.
Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, Battleman DS.
Clin Adv Hematol Oncol. 2008 Oct;6(10):755-60.
Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J, Cibeira MT, Rosiñol L.
Acta Oncol. 2005;44(5):440-8. Review.
A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
Mangiacavalli S, Varettoni M, Zappasodi P, Pica G, Lazzarino M, Corso A.
Leuk Res. 2009 Apr;33(4):577-8. Epub 2008 Oct 7. No abstract available.
Multiple myeloma.
Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC.
Lancet. 2009 Jul 25;374(9686):324-39. Epub 2009 Jun 21. Review.
Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
Laura R, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Bladé J, Montserrat E.
Eur J Haematol. 2006 May;76(5):405-8. Epub 2006 Mar 9.
Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.
Qayum A, Aleem A, Al Diab AR, Niaz F, Al Momen AK.
Saudi J Kidney Dis Transpl. 2010 Jan;21(1):63-8.
Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.
Mateos-Mazon J, Pérez-Simón JA, Lopez O, Hernández E, Etxebarria J, San Miguel JF.
Haematologica. 2007 Sep;92(9):1295-6.
Concurrence of localized Castleman's disease and peripheral small B-Lymphocytic lymphoma within the same lymph node.
Orcioni GF, Mambelli V, Ascani S, Sabattini E, Piccioli M, Pieri F, Falini B, Pileri SA.
Gen Diagn Pathol. 1998 Apr;143(5-6):327-30.
A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.
Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, Onishi Y, Fujiwara Yamada M, Ishizawa K, Kameoka J, Harigae H.
Int J Hematol. 2009 Apr;89(3):342-7. Epub 2009 Mar 19.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on